Zacks Investment Research upgraded shares of Genfit (NASDAQ:GNFT – Get Rating) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has $4.75 target price on the stock.
According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “
GNFT has been the subject of several other research reports. Oddo Bhf upgraded Genfit to a buy rating in a research report on Friday, December 17th. HC Wainwright upgraded Genfit from a neutral rating to a buy rating and set a $8.00 price objective for the company in a research report on Monday, December 20th. Finally, SVB Leerink cut their price objective on Genfit from $15.00 to $10.00 and set an outperform rating for the company in a research report on Monday.
Hedge funds have recently made changes to their positions in the company. OLD Mission Capital LLC purchased a new position in shares of Genfit in the third quarter valued at $213,000. Millennium Management LLC increased its position in shares of Genfit by 23.3% in the fourth quarter. Millennium Management LLC now owns 392,517 shares of the company’s stock valued at $1,963,000 after buying an additional 74,068 shares in the last quarter. Morgan Stanley increased its position in shares of Genfit by 76.7% in the first quarter. Morgan Stanley now owns 64,071 shares of the company’s stock valued at $296,000 after buying an additional 27,818 shares in the last quarter. Finally, Credit Suisse AG purchased a new position in shares of Genfit in the fourth quarter valued at $55,000. Institutional investors and hedge funds own 1.22% of the company’s stock.
Genfit Company Profile (Get Rating)
Genfit SA, a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis.
- Get a free copy of the StockNews.com research report on Genfit (GNFT)
- UiPath Stock is Nearing Rock Bottom Down Here
- Array Technologies Stock Giving Another Ground Floor Entry
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.